NumFin

Celldex Therapeutics, Inc.

Sümbol: CLDX

NASDAQ

40.86

USD

Turuhind täna

  • -15.8077

    P/E suhe

  • -0.2079

    PEG suhe

  • 2.69B

    MRK Cap

  • 0.00%

    DIV tootlus

Celldex Therapeutics, Inc. (CLDX) Finantsaruanded

Download
AastaneQuarterly
LineaarneLog
Diagrammil näete Celldex Therapeutics, Inc. (CLDX) vaikimisi numbreid dünaamikates. Companys revenue näitab keskmist 6.864 M, mis on 0.832 % gowth. Kogu perioodi keskmine brutokasum on 3.162 M, mis on 0.925 %. Keskmine brutokasumi suhtarv on 0.425 %. Ettevõtte eelmise aasta tulemuse puhaskasv on 0.152 %, mis on võrdne -0.692 % % keskmiselt kogu ettevõtte ajaloo jooksul.,

AastaneQuarterly
10Y20Y30Y40Y

Bilanss

Sukeldudes Celldex Therapeutics, Inc. fiskaalkäiguteele, täheldame keskmist varade kasvu. See määr on huvitaval kombel , mis kajastab nii ettevõtte kõrg- kui ka madalseisusid. Kui võrrelda kvartalite lõikes, siis kohandub see näitaja 0. Kui vaadata tagasi möödunud aastale, siis on varade kogumuutus 0.320. Käibevara valdkonnas on CLDX aruandlusvaluutas 431.693. Märkimisväärne osa neist varadest, täpsemalt 421.698, hoitakse sularahas ja lühiajalistes investeeringutes. See segment näitab eelmise aasta andmetega võrreldes muutust 0.383%. Ettevõtte pikaajalised investeeringud, kuigi need ei ole tema fookuses, seisavad 0, kui neid on, aruandlusvaluutas. See näitab erinevust 0.000% võrreldes eelmise aruandeperioodiga, mis kajastab ettevõtte strateegilisi muutusi. Ettevõtte võlaprofiil näitab, et ettevõtte pikaajaline koguvõlg on 0.928 aruandlusvaluutas. See näitaja tähendab, et aastane muutus on -0.370%. Aktsionäride väärtus, mida näitab aktsionäride kogu omakapital, on hinnatud 429.171 aruandlusvaluutas. Selle aspekti aastane muutus on 0.316%. Kui süveneda ettevõtte finantsnäitajatesse, ilmneb täiendavaid üksikasju. Netovõlad on hinnatud 4.528, varude hind on 0 ja firmaväärtus 0, kui see on olemas. Kogu immateriaalne vara, kui see on olemas, hinnatakse 27.19.

common:word.in-mln

USD
Growth
TTM20232022202120202019201820172016201520142013201220112010200920082007200620052004200320022001200019991998199719961995199419931992199119901989198819871986

balance-sheet.row.cash-and-short-term-investments

1188.13421.7305408.3
194.4
64.4
94
139.4
189.8
289.9
201
303
84
53.3
61.1
82.5
44.3
15.7
40.9
23.4
31.7
20.3
25.1
42.7
50.2
13.6
8.9
6.4
12.6
12.3
7.6
28.3
3.3
8.7
11.3
9.6
10.8
13.5
2.4

balance-sheet.row.short-term-investments

1049.84386.9275.5369.1
150.6
53.2
69.7
99.1
147.3
217.8
173
133.6
59.1
41.4
39.8
25.5
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.net-receivables

6.214.50.30.2
1.8
1
3.2
1.9
1.8
1
0.4
0.5
0
0.2
0.3
0.5
1.8
0.3
0.3
0.4
2.2
1.5
0.2
0.3
0.2
0.4
0
0
0.4
0.3
0.6
0.5
0.7
1.1
0.7
0.6
0.4
0.3
0

balance-sheet.row.inventory

-1.430-0.3-0.2
-1.8
-1
-3.2
0
-1.8
-1
-0.4
0
0
0
-0.3
0
0
0
0
0
0
0
71.5
0.1
0.1
0
0
0
0
0.4
0.4
0.4
0.6
0.3
0.4
0.2
0.1
0
0

balance-sheet.row.other-current-assets

39.135.512.72.6
3.4
2.3
5.1
3.4
5.8
5
3.9
1.7
1.2
1.2
1.8
1
1
0.4
1.2
0.8
0.6
0.6
0.6
0.3
1.4
0.4
6.7
1
0.3
0.6
9.1
0.3
14.6
0.5
0.3
0.3
0.3
0.2
0.4

balance-sheet.row.total-current-assets

1232.04431.7317.7410.8
197.8
66.7
99.1
144.8
195.6
294.9
205
305.2
85.1
54.7
62.9
84
47.1
16.4
42.4
24.6
34.5
22.3
25.9
43.3
51.8
14.5
15.6
7.4
13.3
13.6
17.7
29.5
19.2
10.6
12.7
10.7
11.6
14
2.8

balance-sheet.row.property-plant-equipment-net

21.66.63.73.6
3.8
4
6.1
10.4
13.2
11.5
10.5
10
7.2
9.1
10.8
11.5
13.6
16.4
14
5.7
4.2
0.9
1.1
1
1
1.3
1.1
0.4
0.5
1.2
1.1
1.8
2
2
2.2
2
0.9
0.6
0.4

balance-sheet.row.goodwill

3.36000
0
0
0
91
91
9
9
9
9
9
9
9
0
1
1
1036.3
1036.3
1036.3
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.intangible-assets

112.527.231.330.3
34.2
52.2
50.6
67.6
174.6
31.2
32.5
22.8
33.2
34.2
36.2
30
2.5
3.1
4
6.1
7.1
8
8.2
9.2
10.7
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.goodwill-and-intangible-assets

115.8627.231.330.3
34.2
52.2
50.6
158.6
174.6
31.2
32.5
31.8
33.2
34.2
36.2
38.9
2.5
4.1
5
6.1
7.1
8
8.2
9.2
10.7
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.long-term-investments

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.tax-assets

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.other-non-current-assets

0.210.100
0
0
0
1.9
0
0
0
0.1
0
0
0
6
6.7
0.6
0.1
0
0
0.1
0.1
0
0
4.1
6
2
3.4
3.7
1.9
1.8
1.2
0.6
0.7
0.5
0.5
0
0

balance-sheet.row.total-non-current-assets

137.6733.93533.8
38
56.2
56.7
170.9
187.8
42.6
43
41.9
40.4
43.3
47
56.4
22.7
21.2
19.1
11.8
11.3
9
9.4
10.1
11.8
5.4
7.1
2.4
3.9
4.9
3
3.6
3.2
2.6
2.9
2.5
1.4
0.6
0.4

balance-sheet.row.other-assets

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-assets

1369.71465.6352.7444.7
235.8
122.9
155.8
315.6
383.4
337.6
248
347.1
125.5
98
109.9
140.4
69.8
37.6
61.5
36.5
45.8
31.3
35.2
53.5
63.6
19.9
22.7
9.8
17.2
18.5
20.7
33.1
22.4
13.2
15.6
13.2
13
14.6
3.2

balance-sheet.row.account-payables

11.343.53.31.2
1
1.2
1.1
1.7
1.7
1.5
2.6
2.2
0.7
0.9
0.9
1.4
2.2
1.3
2.6
1.1
1.8
0.5
0.8
1.1
0.9
0.6
0.4
0.2
0.3
0.7
0.8
0.5
0.4
0.5
0.8
0
0
0
0

balance-sheet.row.short-term-debt

6.181.61.41.7
1.3
1.9
4.5
6.6
0
4.4
2.6
0
5.6
6.4
1.1
2.2
0.2
0.6
0.5
0.2
3.5
0
0
0
0.3
0.3
1
0.8
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.tax-payables

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.long-term-debt-total

6.110.92.61.3
2.2
1.7
0
0
0
-21.2
0
0
5.7
9
8.9
11.7
0.8
4.6
4.2
0
0
0
0
0
0
0.3
0.6
0.8
0
0.2
0.5
0.5
0
0
0
0
0
0
0

Deferred Revenue Non Current

0000
0
0
0
0
0
16.6
0
0
0
0
0
34.2
36488.7
42270.4
45069.1
0
0
0
0
2693.4
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.deferred-tax-liabilities-non-current

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.other-current-liab

41.582613.81.6
3.4
2
4.5
6.6
33.5
4.4
2.6
18.1
0.4
7
13.2
5.6
6.9
3.1
2.7
-9997.7
0.2
1.5
2.1
2.7
4.2
1.3
1.9
1.8
1.3
1.7
1.8
2.9
2
2.3
1.7
2.5
1.3
1.7
0.5

balance-sheet.row.total-non-current-liabilities

23.725.37.98.7
12.3
17.3
19.1
51.5
82.7
17.2
11.9
7
12.1
15
14.5
52.2
37.6
46.9
49.2
11.9
1.9
1.9
0.5
2.7
4.2
0.3
0.6
0.7
0.3
0.1
0.5
0.6
0.4
0.5
0.8
2.3
2.4
2.5
5.2

balance-sheet.row.other-liabilities

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-1.9
0
0
0
0
0
0
-0.3
0
0
0
-0.4
-0.5
-0.8
0
0
0
0

balance-sheet.row.capital-lease-obligations

10.680.943
3.5
3.7
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-liab

113.5536.526.525.2
26.5
28.9
31.7
79.3
117.9
47.5
36.4
27.3
29.8
29.3
34.7
66.6
51.7
56.7
59.3
15.6
7.4
3.4
3.9
8.2
9.6
2.5
3.9
3.5
1.6
2.5
3.1
4
2.4
2.8
2.5
4.8
3.7
4.2
5.7

balance-sheet.row.preferred-stock

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0.3
1.7
0
0
0
0

balance-sheet.row.common-stock

0.20.100
0
0
0
0.1
0.1
0.1
0.1
0.1
0.1
0
0
0
0
0
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.retained-earnings

-5352.5-1397.4-1255.9-1143.6
-1073.1
-1013.3
-962.4
-812.5
-719.5
-591
-463.8
-345.7
-264.1
-205
-160.2
-157.7
-121.1
-277.9
-256.2
-235.9
-217.8
-204.6
-191.9
-178.1
-155.3
-133.3
-122
-70.2
-57.1
-46.3
-38.1
-26.5
-18.7
-10.5
-7
-6
-4.9
-3.7
-2.9

balance-sheet.row.accumulated-other-comprehensive-income-loss

9.643.31.31.9
2.6
2.6
2.6
2.6
2.5
2.3
2.6
2.7
2.7
2.7
2.8
2.5
2.6
0.1
-5.4
-1.2
-1.5
-1
-4.4
-4
-4.1
-3.5
-2.9
-2.7
-2.5
-3.2
-3
-3.3
0
-1.7
-1.2
-0.7
-0.5
-0.2
-0.1

balance-sheet.row.other-total-stockholders-equity

6598.841823.21580.81561.1
1279.8
1104.7
1083.9
1046.2
982.3
878.7
672.7
662.7
357.1
271
232.7
228.9
136.7
258.8
263.7
257.9
257.6
233.4
227.6
227.2
213.3
154.2
143.7
79.2
75.2
65.5
58.7
58.9
38.4
22.3
19.6
15.1
14.7
14.3
0.5

balance-sheet.row.total-stockholders-equity

1256.17429.2326.2419.5
209.4
94
124.1
236.4
265.4
290.1
211.7
319.8
95.8
68.7
75.3
73.8
18.1
-19
2.2
20.9
38.4
27.9
31.3
45.3
53.9
17.4
18.8
6.3
15.6
16
17.6
29.1
19.7
10.4
13.1
8.4
9.3
10.4
-2.5

balance-sheet.row.total-liabilities-and-stockholders-equity

1369.71465.6352.7444.7
235.8
122.9
155.8
315.6
383.4
337.6
248
347.1
125.5
98
109.9
140.4
69.8
37.6
61.5
36.5
45.8
31.3
35.2
53.5
63.6
19.9
22.7
9.8
17.2
18.5
20.7
33.1
22.4
13.2
15.6
13.2
13
14.6
3.2

balance-sheet.row.minority-interest

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0.3
0
0
0
0
0
0

balance-sheet.row.total-equity

1256.17429.2326.2419.5
209.4
94
124.1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.total-liabilities-and-total-equity

1369.71---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

Total Investments

1049.84386.9275.5369.1
150.6
53.2
69.7
99.1
147.3
217.8
173
133.6
59.1
41.4
39.8
25.5
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-debt

12.292.543
3.5
3.7
4.5
6.6
0
4.4
2.6
0
11.3
15.4
10
13.8
1
5.2
4.6
0.2
2.1
0
0
0
0.3
0.6
1.6
1.6
0
0.2
0.5
0.5
0
0
0
0
0
0
0

balance-sheet.row.net-debt

-126-32.3-25.4-36.1
-40.4
-7.6
-19.8
-33.7
-42.5
-67.7
-25.4
-169.4
-13.6
3.5
-11.3
-43.2
-43.3
-10.5
-36.3
-23.2
-29.6
-20.3
-25.1
-42.7
-49.9
-13.1
-7.3
-4.8
-12.6
-12.1
-7.1
-27.8
-3.3
-8.7
-11.3
-9.6
-10.8
-13.5
-2.4

Rahavoogude aruanne

Celldex Therapeutics, Inc. finantsmaastikul on viimase perioodi jooksul toimunud märkimisväärne muutus vabas rahavoos, mis näitab -0.034 nihet. Ettevõte laiendas hiljuti oma aktsiakapitali, emiteerides 218.46, mis tähistab 19.149 erinevust võrreldes eelmise aastaga. Huvitav on see, et osa ettevõtte aktsiatest, täpsemalt 0, ostis ettevõte ise tagasi. Selle tegevuse tulemusena muutus 0.000 võrreldes eelmise aastaga. Vahepeal on ettevõtte võlgnevused praegu 9.38 aruandlusvaluutas. Ettevõtte investeerimistegevuse tulemusel kasutas ettevõte netosularaha, mis aruandlusvaluutas oli -105782000.000. See on -2.176 nihkumine võrreldes eelmise aastaga. Samal perioodil registreeris ettevõte 3.01, 0, 0, mis on olulised ettevõtte investeerimis-ja tagasimaksestrateegiate mõistmiseks. Ettevõtte finantseerimistegevuse tulemusel kasutas ettevõte netorahavahendeid 0.000, kusjuures erinevus võrreldes eelmise aastaga oli 0.000. Lisaks eraldas ettevõte 0 aktsionäridele dividendide maksmiseks. Samal ajal tegi ta muid finantsmanöövreid, millele viidatakse kui 0, mis samuti mõjutasid oluliselt tema rahavooge sel perioodil. Need komponendid koos annavad tervikliku pildi ettevõtte finantsseisundist ja strateegilisest lähenemisest rahavoogude juhtimisele.

common:word.in-mln

USD
Growth
TTM2023202220212020201920182017201620152014201320122011201020092008200720062005200420032002200120001999199819971996199519941993199219911990198919881987

cash-flows.row.net-income

-141.43-141.4-112.3-70.5
-59.8
-50.9
-151.2
-93
-128.5
-127.2
-118.1
-81.5
-59.1
-44.8
-2.5
-36.5
-47.5
-21.6
-20.4
-18.1
-13.2
-12.7
-13.8
-22.8
-22
-11.3
-51.8
-13.1
-10.8
-8.3
-11.6
-7.8
-3.6
-3.4
-1
-1.1
-1.2
-0.8

cash-flows.row.depreciation-and-amortization

3.0132.93.1
3.9
4.9
3.8
5.3
4.1
4
3.4
2.9
3.1
4.2
5.9
3.5
2.5
2.7
2.1
2.1
1.7
1.5
1.6
2.3
1.3
2
1
0.4
0.5
0.7
0.8
0.9
0.6
0.6
0.5
0.3
0.2
0.2

cash-flows.row.deferred-income-tax

0-22.8-0.2-0.2
-1.2
0.7
-0.8
-24.3
1
0.3
0.1
-1.4
-0.7
0
-0.1
-0.5
-4815.7
-359.1
-1626.8
-538
-328
-115
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.stock-based-compensation

23.8923.915.69
3.9
4.6
8.1
12.3
15.3
12.8
6.9
4.5
2.3
2.3
2.8
3.1
4815.7
359.5
1626.8
538
328
115
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.change-in-working-capital

13.4613.5-3.9-1.1
-0.3
-4.3
-15.4
-12.2
-6.6
10.9
6.1
7.7
4.4
2.4
-37.2
0.9
43.3
-1.3
43.7
10
1.1
-1.8
-4.5
-0.4
7.2
0.7
-2.8
-0.2
-0.8
-0.2
-0.9
1.8
-0.7
-0.3
-0.2
10
-10
12.3

cash-flows.row.account-receivables

-2.28-2.3-0.21.6
-0.8
-0.8
-0.8
-0.1
-0.8
0
0.1
-0.4
0.1
0.2
1.3
1.3
-1655.6
286.8
97.4
1812
-757.5
-1241.9
-113.7
-113.7
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.inventory

0000
0
13.9
1.8
-3.6
-0.7
0
0
0.6
2.3
0.2
-0.3
0.7
443.9
532.6
-1807.9
-193.3
-2566
2247.7
0.1
0
0
0
0
0
0
0
0
0.2
0
0.1
-0.2
0
0
0

cash-flows.row.account-payables

9.389.43.13.7
1.6
-13.1
-13.1
-8.7
-5
0
0
7.2
2.1
2.1
-2.5
-2.5
1221.3
-819.1
1751.3
-1618.7
3323.5
-1005.8
278.2
278.2
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.other-working-capital

9.386.4-6.8-6.3
-1.1
-4.3
-3.3
0.2
-0.1
10.9
6.1
0.3
-0.1
-0.1
-35.7
1.4
33.8
-1.6
2.8
10
1.1
-1.8
-169
-164.9
7.1
0.7
-2.8
-0.2
-0.8
-0.2
-0.9
1.6
-0.7
-0.4
0
10
-10
0

cash-flows.row.other-non-cash-items

-6.2216.6-5.8-1.1
13
-1.3
80.2
12
1.6
0.3
0.1
0.1
0.2
0.3
0.7
-0.3
19.9
0.5
1.6
0
0
1.2
0
0.1
9.1
0.1
44.7
5.2
1.4
-0.1
2.6
-0.4
-0.2
0.1
0
-9.2
11
-11.7

cash-flows.row.net-cash-provided-by-operating-activities

-107.29000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

-1.82-1.8-1.8-1.2
-1.6
-0.7
-0.8
-1.8
-2.8
-4.9
-1.9
-4.2
-0.3
-0.5
-2.1
-0.5
-1.3
-5
-9.3
0
0
-0.2
-0.6
-0.6
-0.2
-0.7
-0.3
-0.1
-0.6
-0.6
-0.8
-0.5
-0.5
-0.4
-0.7
0
0
0

cash-flows.row.acquisitions-net

-13.3800.10
0.1
0
0
1.8
4.6
0
0
0
0
0
0
51.7
11
0
0
-2.2
-3.7
0
0
0
-0.7
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.purchases-of-investments

-424.56-424.6-189-389.9
-220.3
-95.4
-171.2
-171
-175.7
-206.4
-148.3
-112.1
-69.3
-52.7
-56.5
-9.6
0
0
0
0
-2
0
0
0
0
0
0
0
0
0
-1.2
0
-2.5
0
0
0
0
0

cash-flows.row.sales-maturities-of-investments

320.6320.6280.7174.9
123.6
113.2
201.5
219.2
242.8
161.1
109.2
38.9
52.4
51
42.4
3.5
0
0
0
0
4
0
0
0
0
4.9
4.5
0
0
8.5
14
13
0
0
0
0
0
0

cash-flows.row.other-investing-activites

13.38000
0
0
0.3
-1.8
0
0
0
0
0.2
0.1
0.1
0
0.5
-0.7
0
0
0
-2
-0.3
-0.2
-0.1
-0.9
3.4
1.6
0.4
-2
-0.4
-0.7
-0.6
0
-0.2
0
0
0

cash-flows.row.net-cash-used-for-investing-activites

-105.78-105.889.9-216.2
-98.2
17.1
29.8
46.5
68.9
-50.2
-41
-77.4
-17
-2.2
-16.2
45.1
10.2
-5.7
-9.3
-2.2
-1.7
-2.2
-0.8
-0.8
-1
3.3
7.6
1.5
-0.2
5.9
11.6
11.8
-3.6
-0.4
-0.9
0
0
0

cash-flows.row.debt-repayment

0000
-3
0
0
0
0
0
0
-11
-4
-12.5
-0.2
-3.1
-102.4
-244.3
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.common-stock-issued

218.46218.54.1269.9
170.8
16.2
29
51
13.9
188.8
0
295.7
83.8
36
1
0.7
10.9
0
0
0
23.4
9.2
0
14.1
42
10
3.7
0
10.2
6.6
0
17.2
0.3
0.8
3.4
0
0
0

cash-flows.row.common-stock-repurchased

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-0.1
-0.1
0
0
0
0
0
0
-0.1
0
0
0
0
0
0
0
0

cash-flows.row.dividends-paid

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.other-financing-activites

0.6904.12.5
3.4
0
0.4
0.3
0.5
4.3
1.2
4.9
-0.1
4.9
10
0
102.4
244.1
-0.2
-0.2
2.1
0
0
0
0
0
0
0
0
0.2
0
0.5
0
0
0
0
0
0

cash-flows.row.net-cash-used-provided-by-financing-activities

218.46218.54.1272.4
171.2
16.3
29.4
51.3
14.5
193.2
1.2
289.6
79.8
28.4
10.8
-2.5
10.9
-0.2
-0.2
-0.1
25.5
9.1
-0.1
14.1
42
10
3.7
0
10.2
6.7
0
17.7
0.3
0.8
3.4
0
0
0

cash-flows.row.effect-of-forex-changes-on-cash

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0.1
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.net-change-in-cash

5.385.4-9.7-4.7
32.6
-13.1
-16
-2.2
-29.6
44.1
-141.4
144.5
13
-9.4
-35.7
12.7
39.3
-25.3
17.5
-8.3
13.5
-4.8
-17.6
-7.5
36.6
4.7
2.5
-6.2
0.3
4.7
2.5
24
-7.2
-2.6
1.8
0
0
12.3

cash-flows.row.cash-at-end-of-period

138.2934.829.439.1
43.8
11.2
24.3
40.3
42.5
72.1
28
169.4
24.9
11.9
21.3
57
44.3
15.7
40.9
23.4
31.7
20.3
25.1
42.7
50.2
13.6
8.9
6.4
12.6
12.3
7.7
28.3
3.4
8.7
11.4
0
0
12.3

cash-flows.row.cash-at-beginning-of-period

132.9129.439.143.8
11.2
24.3
40.3
42.5
72.1
28
169.4
24.9
11.9
21.3
57
44.3
4.9
40.9
23.4
31.7
18.3
25.1
42.7
50.2
13.6
8.9
6.4
12.6
12.3
7.6
5.2
4.3
10.6
11.3
9.6
0
0
0

cash-flows.row.operating-cash-flow

-107.29-107.3-103.7-60.9
-40.4
-46.4
-75.2
-99.9
-113
-98.9
-101.5
-67.7
-49.8
-35.7
-30.4
-29.9
18.3
-19.3
27
-6
-10.3
-11.7
-16.7
-20.8
-4.4
-8.5
-8.9
-7.7
-9.7
-7.9
-9.1
-5.5
-3.9
-3
-0.7
0
0
12.3

cash-flows.row.capital-expenditure

-1.82-1.8-1.8-1.2
-1.6
-0.7
-0.8
-1.8
-2.8
-4.9
-1.9
-4.2
-0.3
-0.5
-2.1
-0.5
-1.3
-5
-9.3
0
0
-0.2
-0.6
-0.6
-0.2
-0.7
-0.3
-0.1
-0.6
-0.6
-0.8
-0.5
-0.5
-0.4
-0.7
0
0
0

cash-flows.row.free-cash-flow

-109.11-109.1-105.6-62.2
-42
-47.1
-76
-101.7
-115.8
-103.8
-103.5
-71.9
-50.1
-36.2
-32.5
-30.4
17
-24.3
17.7
-6
-10.3
-11.9
-17.2
-21.4
-4.6
-9.2
-9.2
-7.8
-10.3
-8.5
-9.9
-6
-4.4
-3.4
-1.4
0
0
12.3

Kasumiaruande rida

Celldex Therapeutics, Inc. tulud muutusid võrreldes eelmise perioodiga 1.920%. CLDX brutokasum on teatatud 3.88. Ettevõtte tegevuskulud on 145.92, mille muutus võrreldes eelmise aastaga on 33.315%. Kulud amortisatsioonikulud on 3.01, mis on -0.775% muutus võrreldes eelmise aruandeperioodiga. Tegevuskulud on teatatud 145.92, mis näitab 33.315% muutust võrreldes eelmise aastaga. Müügi- ja turunduskulud on 0, mis on 0.000% muutus võrreldes eelmise aastaga. Hiljutistel numbritel põhinev EBITDA on 0, mis tähendab -0.233% kasvu võrreldes eelmise aastaga. Tegevustulu on -142.04, mis näitab 0.233% muutust võrreldes eelmise aastaga. Puhaskasumi muutus on 0.152%. Eelmise aasta puhaskasum oli -141.43.

common:word.in-mln

USD
Growth
TTM20232022202120202019201820172016201520142013201220112010200920082007200620052004200320022001200019991998199719961995199419931992199119901989198819871986

income-statement-row.row.total-revenue

6.886.92.44.7
7.4
3.6
9.5
12.7
6.8
5.5
3.6
4.1
11.2
9.3
46.8
15.2
7.5
5.1
4.9
3.1
6.9
4.6
6.7
3.3
0.8
1.5
2.2
1.2
1.1
4
7
9
6.6
10.2
10.9
7.8
4.6
2.2
0.1

income-statement-row.row.cost-of-revenue

3.0131.43.1
42.5
42.7
0
0
0
0
0
2.3
10.8
9.1
12.1
8.4
0
0
0
0
0
0
0
0
-0.7
-0.7
-0.4
-0.3
-0.1
1.2
1.2
1.5
0.6
1.1
0.8
0.8
0.3
-0.1
0

income-statement-row.row.gross-profit

3.883.911.6
-35.1
-39.1
9.5
12.7
6.8
5.5
3.6
1.8
0.4
0.1
34.7
6.8
7.5
5.1
4.9
3.1
6.9
4.6
6.7
3.3
1.5
2.2
2.6
1.5
1.2
2.8
5.8
7.5
6
9.1
10.1
7
4.3
2.3
0.1

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.research-development

117.25---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-general-administrative

30.91---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-expenses

130.23130.290.355.4
54
42.7
0.2
0.9
1
1
1
1
1.1
1.9
3.1
0.3
0.4
1
1
1
1
1
0.8
1.4
1.3
2
1
0.4
0.5
0.7
0.8
0.9
0.6
0.6
0.5
0.3
0.2
0.2
0.1

income-statement-row.row.operating-expenses

148.17145.9109.573.8
57
58.1
85.9
122.1
139.7
135
126
83.2
58.5
43.6
41.2
43.6
41.5
28
27.3
22
20.4
16.4
21.1
27.9
16.9
14.1
10.5
9.2
13
14.6
15.3
16.9
10.7
13.5
12
8.6
6.3
3.9
2

income-statement-row.row.cost-and-expenses

148.93148.9109.573.8
57
58.1
85.9
122.1
139.7
135
126
85.6
69.3
52.7
53.2
52
41.5
28
27.3
22
20.4
16.4
21.1
27.9
16.2
13.4
10.1
8.9
12.9
15.8
16.5
18.4
11.3
14.6
12.8
9.4
6.6
3.8
2

income-statement-row.row.interest-income

13.1113.12.90.5
2.4
4.2
0
0
0
0
0
0
0.5
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.interest-expense

00-2.90
0
0
151.1
16
0
0
0
0.9
1.6
1.8
1.3
0.5
0
-2.2
-4.2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.total-other-income-expensenet

0.610.62.90.5
2.4
4.2
-75.5
-8
4.4
2.3
4.3
0.8
0.5
0.4
5.3
0.2
-13.5
1.1
2.1
0.8
0.4
0.2
0.6
1.8
-6.5
0.6
-43.8
-5.5
1
3.6
-2.1
1.2
0.8
0.9
0.8
0.7
0.8
0.9
0.1

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-operating-expenses

130.23130.290.355.4
54
42.7
0.2
0.9
1
1
1
1
1.1
1.9
3.1
0.3
0.4
1
1
1
1
1
0.8
1.4
1.3
2
1
0.4
0.5
0.7
0.8
0.9
0.6
0.6
0.5
0.3
0.2
0.2
0.1

income-statement-row.row.total-operating-expenses

0.610.62.90.5
2.4
4.2
-75.5
-8
4.4
2.3
4.3
0.8
0.5
0.4
5.3
0.2
-13.5
1.1
2.1
0.8
0.4
0.2
0.6
1.8
-6.5
0.6
-43.8
-5.5
1
3.6
-2.1
1.2
0.8
0.9
0.8
0.7
0.8
0.9
0.1

income-statement-row.row.interest-expense

00-2.90
0
0
151.1
16
0
0
0
0.9
1.6
1.8
1.3
0.5
0
-2.2
-4.2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.depreciation-and-amortization

-0.83313.43.7
25.2
-3.1
0.2
5.3
1
1
1
2.9
1.1
1.9
3.1
3.5
2.5
2.7
2.1
2.1
1.7
1.5
1.6
2.3
1.3
2
1
0.4
0.5
0.7
0.8
0.9
0.6
0.6
0.5
0.3
0.2
0.2
0.1

income-statement-row.row.ebitda-caps

-149.31---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.operating-income

-142.04-142-115.2-71.2
-63.4
-55
-156.4
-121.5
-132.9
-129.5
-122.4
-81.4
-58.1
-43.4
-6.5
-36.9
-48.8
-22.9
-22.4
-18.9
-13.6
-11.7
-14.4
-24.6
-15.4
-11.9
-7.9
-7.7
-11.8
-11.8
-9.5
-9.4
-4.7
-4.4
-1.9
-1.6
-2
-1.6
-1.9

income-statement-row.row.income-before-tax

-141.43-141.4-112.3-70.7
-60.9
-50.9
-151.9
-117.3
-128.5
-127.2
-118.1
-81.5
-59.1
-44.8
-2.5
-37.1
-62.3
-21.8
-20.3
-18.1
-13.2
-11.5
-13.8
-22.8
-22
-11.3
-7.9
-13.2
-10.8
-8.2
-11.6
-8.2
-3.9
-3.5
-1.1
-0.9
-1.2
-0.7
-1.8

income-statement-row.row.income-tax-expense

0010.5-0.2
-1.2
-0.5
-0.8
-24.3
-8.8
-2.3
-4.3
-0.8
-0.5
-0.4
-5.3
-0.5
27
-0.1
0.1
-1.5
-0.8
0.7
-1.2
-3.6
13.1
-1.3
87.7
10.9
-2
-7.1
4.2
-2.8
-1.9
-1.9
-1.7
-1.2
-1.6
-1.7
-0.3

income-statement-row.row.net-income

-134.48-141.4-122.8-70.5
-59.8
-50.4
-151.2
-93
-128.5
-127.2
-118.1
-81.5
-59.1
-44.8
-2.5
-36.5
-47.5
-21.6
-20.4
-18.1
-13.2
-12.7
-13.8
-22.8
-22
-11.3
-51.8
-13.1
-10.8
-8.3
-11.6
-7.8
-3.6
-3.4
-1
-1.1
-1.2
-0.8
-1.7
Sarnased aktsiad
Sind võib huvitada ka:
SRNE
Sorrento Therapeutics, Inc..
0.014 USD
NASDAQ
MRVI
Maravai LifeSciences Holdings, Inc..
8.8 USD
NASDAQ
CMRA
Comera Life Sciences Holdings, Inc..
0.03 USD
NASDAQ
GUBRA.CO
Gubra A/S.
296 DKK
CPH
T5O.DE
CytoTools AG.
0.468 EUR
XETRA
HBC.OL
Hofseth BioCare ASA.
2.04 NOK
OSL
6826.HK
Shanghai Haohai Biological Technology Co., Ltd..
42.05 HKD
HKSE
PPBT
Purple Biotech Ltd..
0.67 USD
NASDAQ

Korduma kippuv küsimus

Mis on Celldex Therapeutics, Inc. (CLDX) koguvara?

Celldex Therapeutics, Inc. (CLDX) koguvara on 465627000.000.

Mis on ettevõtte aastane tulu?

Aastane tulu on 5648000.000.

Mis on ettevõtte kasumimarginaal?

Ettevõtte kasumimarginaal on 0.563.

Mis on ettevõtte vaba rahavoog?

Vaba rahavoog on -2.097.

Mis on ettevõtte puhaskasumimarginaal?

Puhaskasumimarginaal on -19.538.

Mis on ettevõtte kogutulu?

Kogutulu on -20.637.

Mis on Celldex Therapeutics, Inc. (CLDX) puhaskasum (puhaskasum)?

Puhaskasum (netotulu) on -141429000.000.

Kui suur on ettevõtte koguvõlg?

Koguvõlg on 2542000.000.

Mis on tegevuskulude arv?

Tegevuskulud on 145917000.000.

Milline on ettevõtte rahaline näitaja?

Ettevõtte raha on 34814000.000.